Verve Therapeutics, Inc.
Clinical trials sponsored by Verve Therapeutics, Inc., explained in plain language.
-
Gene editing breakthrough targets stubborn high cholesterol
Disease control Recruiting nowThis study tests a new gene editing treatment called VERVE-102 for people with inherited high cholesterol or early heart disease who need extra help lowering their LDL cholesterol. The treatment aims to turn off a gene in the liver to reduce cholesterol levels. The study involves…
Phase: PHASE1 • Sponsor: Verve Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
Gene-Editing shot aims to slash stubborn cholesterol in early human test
Disease control Recruiting nowThis early-stage study tests a single dose of VERVE-201, a gene-editing treatment, in 36 adults with high cholesterol and triglycerides that don't respond to standard therapies. The treatment aims to turn off a liver gene (ANGPTL3) to lower fat levels in the blood. The main goal …
Phase: PHASE1 • Sponsor: Verve Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:51 UTC